{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Feadv24gooderham-8NDbpgIE","width":444,"version":"1.0","type":"rich","title":"Melinda Knows Best: EADV 2024 Amsterdam with Dr.Melinda Gooderham ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/d9af6bfd-d3df-4686-b79a-8ca4a675708b/copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-76.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"πŸŽ™ Amsterdam Stories, Delta Force & A Game-Changing Topical for Chronic Hand Eczema\n\nπŸŽ‰βœ¨ Melinda Knows Best is BACK! πŸš€πŸ’₯\n\nThis time, Dr. Gooderham brings us a heavyweight showdown πŸ₯Š between a new topical superhero πŸ¦Έβ€β™€οΈ and the reigning oral champ πŸ’Š in the battle against Chronic Hand Eczema! reporting live from the European Academy of Dermatology and Venereology (EADV) Congress in the beautiful city of Amsterdam! πŸ‡³πŸ‡±βœ¨\n\nIn this special episode, we’re diving into the Delta Force Trial – a bold study comparing topical delgocitinib to oral alitretinoin for chronic hand eczema πŸ’ŠπŸ§΄\n\nπŸ‘€ Dr. Gooderham spills the beans on impressive results, rapid relief, and how this new treatment is about to change the game for dermatologists and patients alike. πŸŽ‰\n\nOh, and don’t worry, we didn’t forget to ask about her Amsterdam adventures! 🌍 Did she run into some famous faces at dinner? πŸ½οΈπŸ‘€ Tune in for the scoop!\n\nπŸ’‘ Melinda Knows Best will keep you at the cutting edge of CHE breakthroughs. πŸ‘©β€βš•οΈβœ¨\n\n\n\n🎯 Learning Objectives:\n\nExplore the Delta Force Trial Findings: Understand the significance of the Delta Force trial comparing topical delgocitinib to oral alitretinoin for chronic hand eczema. πŸ§΄πŸ’Š\nEvaluate the Efficacy of Topicals vs Orals for chronic hand eczema: Learn about the early onset of symptom relief with delgocitinib, including i reductions in HEXI scores and patient quality of life improvements. β±οΈπŸ“‰\nIdentify Key Real-World Implications: Discuss how this new topical treatment can shift the landscape for clinicians and patients, offering rapid, safe relief without the headaches (literally!) of oral therapies. πŸ’‘\n Dive into secondary endpoints, including itch and pain relief, and how this data compares to other major clinical trials in hand eczema treatment. πŸ“ŠπŸ”¬\n\n\n\nABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)\n\nToronto, ON\n\nMelinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.\n\nDr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.\n\nπŸ“»www.skinandjoints.ca\n\nβœ‰οΈinfo@skinandjoints.ca\n\n\n\n"}